Posted by Michael Wonder on 05 Aug 2015
Proposal to fund febuxostat (Adenuric) for treatment-resistant gout
7 April 2014 -
PHARMAC is seeking feedback on a proposal to fund febuxostat (Adenuric) for treatment-resistant gout from 1 June 2014, subject to Special Authority criteria in the community and restrictions in DHB hospitals, through a provisional agreement with Te Arai BioFarma.
For more details, go to: http://www.pharmac.health.nz/news/consultation-2014-04-07-febuxostat/
Posted by:
Michael Wonder
Posted in:
